{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-035860","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2025-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.831755+00:00","generated_at":"2026-05-16T18:11:32.335423+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Contineum's PIPE-307 Phase 2 RRMS trial misses primary endpoint","bullets":["Phase 2 VISTA trial of M1 receptor antagonist PIPE-307 did not meet primary or secondary efficacy endpoints.","No significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms.","PIPE-307 demonstrated acceptable safety and tolerability at both doses.","Company will continue to analyze exploratory endpoints and plans future medical meeting presentation.","CEO and CMO express disappointment; focus remains on inflammatory and fibrotic disease pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-035860","json":"https://secwatch.observer/filing/0001437749-25-035860.json","markdown":"https://secwatch.observer/filing/0001437749-25-035860.md","text":"https://secwatch.observer/filing/0001437749-25-035860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925035860/0001437749-25-035860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925035860/ctnm20251117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:11:32.335423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}